$2 One-Drop Blood Test Detects Hidden Diseases in 15 Minutes
A new ultra-sensitive blood test from Arizona State University (ASU) promises lab-grade results almost anywhere—using just a single drop of blood, about $2 worth of consumables, and ~15 minutes to read out. The platform, called NasRED (Nanoparticle-Supported Rapid Electronic Detection), targets infections such as COVID-19, Ebola, HIV/AIDS, and Lyme disease and is designed to expand access to early, accurate diagnosis in clinics, emergency settings, and low-resource communities. ASU NewsMedical XpressSciTechDaily
What exactly is NasRED?
NasRED is a portable diagnostic system that uses engineered gold nanoparticles to detect disease markers at extremely low concentrations. It aims to combine the ease of a rapid antigen card with sensitivities that rival—or exceed—traditional lab tests, but without specialized equipment or training. In ASU’s report, the consumable cost per test is estimated at about $2, with results in ~15 minutes. ASU NewsSciTechDaily
How does it work?
-
Smart nanoparticles: Gold nanoparticles are coated with capture molecules. Some carry antibodies to latch onto pathogen proteins (antigens). Others carry antigens to capture the body’s antibodies. ASU NewsMedical Xpress
-
Mix with a tiny sample: A fraction of a drop of blood (or saliva/nasal fluid) is mixed with the particles. If target molecules are present, the nanoparticles aggregate and sink. If not, they stay suspended. ASU News
-
Optical readout: The device shines LED light through the top of the tube and electronically measures how much light passes. More light → more settling → target detected. ASU News
This physical readout avoids complex amplification steps and keeps the device simple and robust.
How sensitive is it?
Very. ASU reports detection at sub-femtomolar down to attomolar levels—on the order of a few hundred molecules—which they describe as nearly 100,000× lower concentration than many standard tests need. In head-to-head comparisons, the study says NasRED was about 3,000× more sensitive than ELISA, required 16× less sample, and delivered results ~30× faster. ASU NewsSciTechDaily
Early evaluations with actual coronavirus particles showed sensitivities comparable to Abbott ID NOW, a widely used molecular test, while maintaining the portability of a rapid assay. ASU News
What diseases can it find?
The platform is modular: by swapping the proteins on the nanoparticles, the same reader can be tuned to many targets. Demonstrations and prior work cited by the team include SARS-CoV-2 (virus or antibodies), Ebola, Lyme disease, and markers related to HIV/HCV, cancer, Alzheimer’s proteins, and Shiga-toxin E. coli. This adaptability is key for emerging outbreaks and “hard-to-catch” infections that currently go undiagnosed. ASU NewsSciTechDaily
Why this matters
-
Early detection = better outcomes: Infectious diseases cause >10 million deaths/year globally, with delays in testing fueling spread and complications. In the U.S., diagnostic errors contribute to ~800,000 deaths or permanent disabilities annually. Faster, easier testing can bring treatment forward. ASU NewsMedical Xpress
-
Access and equity: Many communities lack reliable labs and trained staff. A compact reader plus $2 cartridges could enable frequent screening in rural clinics, refugee camps, and at the point of care. ASU News
-
Public-health agility: During low-prevalence or early-outbreak phases, running conventional lab workflows for a handful of patients is costly and slow. NasRED’s sensitivity and speed can help catch cases before outbreaks accelerate. ASU News
What are the limits today?
-
Prototype stage: The peer-reviewed study (published in ACS Nano on August 11, 2025) presents research-grade data. The system will need regulatory evaluation (e.g., FDA/CE marks) before clinical deployment. SciTechDaily
-
Some bench steps remain: Current prototypes still use small benchtop spinner/mixer units. The team is working to miniaturize and automate these steps en route to truly handheld or at-home formats. ASU News
-
Menu per target: Each disease target requires appropriate capture chemistry and validation. “Hidden diseases” here means hard-to-detect infections and low-level markers—not a single test that diagnoses every possible condition at once. ASU News
Where could it be used first?
-
Primary care & urgent care: Rule-in/rule-out infectious causes in minutes, guiding immediate treatment or isolation.
-
Screening programs: Regular testing for HIV/HCV in at-risk groups, where lab access is limited.
-
Outbreak response: Rapid deployment for novel or re-emerging pathogens by swapping in new capture reagents.
-
Low-resource settings: Rural clinics and mobile units where power and equipment are scarce. ASU News
Practical takeaways
-
What it is: A portable, low-cost nanoparticle test with electronic optical readout.
-
Why it’s exciting: Attomolar-range sensitivity, ~$2 consumables, 15-minute results.
-
What to watch: Regulatory studies, menu expansion (which diseases become validated first), and hardware miniaturization for home use. ASU NewsMedical Xpress
Sources
-
ASU News: overview of NasRED, cost, speed, sensitivity, diseases, and roadmap (published August 12, 2025). ASU News
-
ACS Nano (2025): peer-reviewed study describing sub-femtomolar detection of SARS-CoV-2 antibodies/antigens (DOI: 10.1021/acsnano.5c12083). SciTechDaily
-
MedicalXpress summary (published August 13, 2025): portability, $2 consumable estimate, modularity, and comparisons to ELISA/PCR. Medical Xpress
